Pain-indicated buprenorphine prescribing in the United States, 2017–2025: national trends, state policy approaches, and payer patterns in a longitudinal ecological study

Background Buprenorphine offers an analgesic option for selected adults with chronic pain. National trends in pain-indicated buprenorphine prescribing, variation across state policy approaches, and consistency within multiple insurance payers have not been examined together. We described national and state prescribing trends, compared growth among states with documented policies, and examined whether state patterns persisted among Medicaid recipients. Methods Longitudinal ecological analysis of 2017-2025 prescription claims for 867,591 unique adults receiving transdermal or buccal buprenorphine across 888 three-digit ZIP code areas, with a systematic policy review of the 50 states and District of Columbia. Outcomes were annual recipients of pain-indicated formulations per 100,000 adults, observed and modeled with a hierarchical Bayesian model (95% credible intervals), state policy characteristics, and payer-restricted rates. Results The observed national rate increased from 53.59 to 78.04 recipients per 100,000 adults (45.6%; 4.81% annualized); model-derived average annual growth was 5.04% (95% credible interval, 2.88%-7.28%). The policy review identified distinct guidance, coverage, oversight, and educational approaches. Annualized growth was 25.43% in Minnesota, 13.50% in Colorado, 6.29% in North Carolina, 3.35% in Virginia, 2.99% in California, 0.63% in West Virginia, 0.50% in Oregon, and −2.96% in Mississippi. Identifiable-Medicaid prescribing grew 3.10% annualized nationally versus 4.81% for all payers and increased in Colorado and Minnesota, but declined in Virginia and North Carolina, where plan coding and managed-care transitions limited Medicaid identification. Conclusions Prescribing increased nationally but varied substantially across states with different policy approaches, and Medicaid-restricted patterns did not consistently mirror all-payer trends. Policy content, timing, and payer reach warrant evaluation; however, these ecological comparisons do not establish causation.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-13
DOI
https://doi.org/10.64898/2026.11.12.26367897
Primary Topic
Opioid Use Disorder Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pain-indicated buprenorphine prescribing in the United States, 2017–2025: national trends, state policy approaches, and payer patterns in a longitudinal ecological study

Cara McDonnell, Robert W. Hurley, Meredith C B Adams, David Kline et al.
2 links
medRxiv
Opioid Use Disorder Treatment
preprint

Pain-indicated buprenorphine prescribing in the United States, 2017–2025: national trends, state policy approaches, and payer patterns in a longitudinal ecological study

Cara McDonnell, Robert W. Hurley, Meredith C B Adams, David Kline, Jae C Yong
preprint en

Abstract

Background Buprenorphine offers an analgesic option for selected adults with chronic pain. National trends in pain-indicated buprenorphine prescribing, variation across state policy approaches, and consistency within multiple insurance payers have not been examined together. We described national and state prescribing trends, compared growth among states with documented policies, and examined whether state patterns persisted among Medicaid recipients. Methods Longitudinal ecological analysis of 2017-2025 prescription claims for 867,591 unique adults receiving transdermal or buccal buprenorphine across 888 three-digit ZIP code areas, with a systematic policy review of the 50 states and District of Columbia. Outcomes were annual recipients of pain-indicated formulations per 100,000 adults, observed and modeled with a hierarchical Bayesian model (95% credible intervals), state policy characteristics, and payer-restricted rates. Results The observed national rate increased from 53.59 to 78.04 recipients per 100,000 adults (45.6%; 4.81% annualized); model-derived average annual growth was 5.04% (95% credible interval, 2.88%-7.28%). The policy review identified distinct guidance, coverage, oversight, and educational approaches. Annualized growth was 25.43% in Minnesota, 13.50% in Colorado, 6.29% in North Carolina, 3.35% in Virginia, 2.99% in California, 0.63% in West Virginia, 0.50% in Oregon, and −2.96% in Mississippi. Identifiable-Medicaid prescribing grew 3.10% annualized nationally versus 4.81% for all payers and increased in Colorado and Minnesota, but declined in Virginia and North Carolina, where plan coding and managed-care transitions limited Medicaid identification. Conclusions Prescribing increased nationally but varied substantially across states with different policy approaches, and Medicaid-restricted patterns did not consistently mirror all-payer trends. Policy content, timing, and payer reach warrant evaluation; however, these ecological comparisons do not establish causation.

medRxiv
Wake Forest University Health Sciences (US), Wake Forest University (US)
Good health and well-being
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon